NeuBase Therapeutics plans dissolution as finances fall apart
The once-promising Pittsburgh biotech firm that developed precision genetic medicines set a board vote for May 13.
Stay updated with breaking news from Todd Branning. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The once-promising Pittsburgh biotech firm that developed precision genetic medicines set a board vote for May 13.
Phathom Pharmaceuticals Announces Proposed Public Offering of 2,250,000 Shares of Common Stock Phathom Pharmaceuticals Announces Proposed Public Offering of 2,250,000 Shares of Common Stock FLORHAM PARK, N.J., Dec. 15, 2020 — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell, subject to market and other conditions, 2,250,000 shares of its common stock in an underwritten public offering. In addition, Phathom in...